Join the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit
As lipid-based therapeutics continue to advance, developers face growing pressure to deliver precise, tissue-specific targeting beyond the liver — without compromising safety, potency, or scalability.
Across pharma and biotech, delivery scientists are repeatedly tackling the same core challenges:
- Accurately characterizing targeted LNPs to uncover particle heterogeneity and confirm ligand integrity.
- Achieving precise extrahepatic delivery to immune cells, muscle, adipose tissue, tumors, and more – while maintaining robust efficacy.
- Balancing safety, potency, and manufacturability when deciding between passive and active targeting
What’s the Answer?
The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit brings together the experts actively solving these challenges — sharing practical, data-driven strategies across formulation, targeting, analytics, and scale-up.
Across 3 days, you’ll gain:
- Technical case studies from 23+ industry experts exploring novel targeting ligands, PEG alternatives, advanced analytics, and next-generation delivery platforms.
- Insights into real-world approaches for optimizing extrahepatic biodistribution, minimizing liver accumulation, and supporting repeat dosing.
- Unmatched peer-to-peer networking with non-viral delivery specialists, where every conversation accelerates selective, specific delivery.
Hear directly from leaders at AbbVie, AstraZeneca, Novo Nordisk, Editas Medicine, Moderna, Mote Therapeutics, Strand Therapeutics, Stylus Medicine, and more.
Where & When
5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit | June 2–4, 2026 | Boston, MA
Discover the Sessions Shaping the Future of Non‑Viral Delivery: https://ter.li/4hs1bsk2
If you’re working to unlock safe, scalable, and tissue-specific delivery beyond the liver, this is the meeting designed around your most pressing challenges.
Make sure to register by Friday, April 17 to save up to $600! You can view your registration options here: https://ter.li/g01yx2k